Compare Nebius Group NV (NBIS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs State Street SPDR S&P Biotech ETF — how do they compare? Nebius Group NV trades at $219.3 (market cap $46.37B), while State Street SPDR S&P Biotech ETF trades at $154.42. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| NBIS | XBI | |
|---|---|---|
Market Cap | $46.37B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $286.69 | $164.28 |
52-Week Low | $50.40 | $85.16 |
Enterprise Value | $46.56B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
